Overview
Precision Medicine marks a transformative era in healthcare to revolutionize disease prevention, diagnosis, and treatment. Realizing this vision calls for paradigm-shifting analytical tools and robust biomarkers for population screening, early cancer diagnosis, and personalized therapy. Working at the nexus of chemistry, nanomaterials, bioengineering, and medicine, our group strives to develop innovative micro/nanoscale technologies to tackle pressing clinical challenges, including cancer, infectious diseases, and neurodegenerative diseases. Our innovations span advanced bioassays, lab-on-a-chip systems, and next-generation biosensing modalities empowered by CRISPR/Cas systems, nanobiohybrids, robotics and artificial intelligence (AI). We aim to create new analytical capabilities for the quantitative, sensitive, and accurate measurement of diverse biomarkers and liquid biopsies, including proteins, nucleic acids, glycans, exosomes, and tumor cells. In close collaboration with clinicians, our long-term interest lies in translational research to advance laboratory innovations into clinical utilities that improve patient outcomes. Our research programs have been continuously supported by the National Institutes of Health and other funding agencies.
Some specific research areas are briefly introduced below. Postdoc scholars, graduate students, and undergraduates interested in our research are encouraged to contact us for more information.
Some specific research areas are briefly introduced below. Postdoc scholars, graduate students, and undergraduates interested in our research are encouraged to contact us for more information.
